Physicians' Academy for Cardiovascular Education
The phase III DAPA-CKD trial evaluating the effectivity of SGLT2 inhibitor dapagliflozin in patients with CKD will be stopped early due to overwhelming benefit.
ACC 2020 COMPASS Diabetes compared treatment of low-dose rivaroxaban plus aspirin with aspirin alone in stable CAD and/or PAD patients with or without diabetes.
ACC 2020 This pre-specified analysis of the COMPASS trial showed that low-dose rivaroxaban plus aspirin reduces CV events compared to aspirin alone in patients with CAD and/or PAD, irrespective of the presence of diabetes.
Using data from the MESA study, it was demonstrated that individuals with irregular sleep duration and timing have increased risk of CVD.
The FDA has released a draft guidance for industry on the evaluation of safety of new T2DM drugs, and has withdrawn the guidance from 2008 with recommendations for evaluation of CV risk.
An analysis of the EUROASPIRE V survey showed that dysglycemia in CAD patients was unrecognized in a large portion of patients, while two thirds of CAD patients have T2DM or IGT.
This post hoc analysis of the DM-DYSLIPIDEMIA study shows that, in a high risk subgroup of T2DM patients with mixed dyslipidemia, alirocumab treatment is more effective in reducing ApoB and non-HDL-c as compared to usual treatment.
The SGLT2 inhibitor dapagliflozin reduced time to first event of atrial fibrillation and atrial flutter as well as total events in T2DM patients, shown in a post-hoc analysis of the DECLARE-TIMI 58 trial.
This subanalysis of the ACCELERATE trial showed that HbA1c levels at study baseline are associated with CV outcomes in T2DM patients with a history of coronary artery disease and on optimal medical therapy.
This study evaluated a community-based screening approach in 8 barbershops in Brooklyn, New York and found a prevalence of undiagnosed diabetes in 9.0% of the black male participants.
The European Society of Cardiology (ESC) Atlas working group has published a report on CVD statistics in 2019 across 56 member countries of the ESC.
Prof. Verma shares the data of subanalyses of the LEADER and SUSTAIN-6 trials on the effect of GLP-1RA treatment in T2DM patients with peripheral artery disease.
